Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Faxcal XT is a multi-ingredient nutritional supplement and pharmaceutical product developed and marketed by Atlina Life Sciences. It is formulated to support bone health and address nutritional deficiencies associated with metabolic and neurological disorders. The product contains calcium carbonate, which provides elemental calcium for bone mineralization, and cholecalciferol (vitamin D3), which facilitates calcium absorption by activating the vitamin D receptor. Additionally, it includes the active forms of several B-vitamins: methylcobalamin (B12), levomefolate calcium (folate), and pyridoxal 5-phosphate (B6). These vitamins play crucial roles in nerve health and homocysteine metabolism. Faxcal XT is primarily used in the management of conditions such as osteoporosis, osteomalacia, and various vitamin and mineral deficiencies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium carbonate + cholecalciferol + methylcobalamin + levomefolate calcium + pyridoxal 5-phosphate.